Gene test may predict dangerous side effects in breast cancer treatment

NCT ID NCT07582887

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether certain gene variants (UGT1A1) increase the risk of severe side effects from powerful breast cancer drugs called antibody-drug conjugates. Researchers will enroll 70 adults with advanced breast cancer who are starting treatment with sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan. By analyzing participants' genes and tracking their side effects, the study aims to develop a way to predict who is most at risk, potentially leading to safer, more personalized treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Universitario Clínico San Cecilio

    RECRUITING

    Granada, Granada, 18016, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact